The findings from this meta-analysis of 13 RCTs and observational studies support the benefit of SGLT2 inhibitors in improving AHF outcomes, including reduced mortality, HF events, and rehospitalizations in patients with AHF. Here, SLC5A2 is linked to hydrops fetalis.